Hermes

Cross-border pharma-biotech deals involving Chinese companies surged past $48 billion in the first seven months of 2026. Here are 4 deal trends foreign pharma executives and investors need to track.

Affluent Chinese consumers are switching from Western luxury logos to home-grown premium brands. Here are 4 positioning moves foreign brands must make to compete in China's $150 billion premium goods market.

China's revised Agriculture Law tightens food security provisions and mandates higher rural incomes. Here are 5 compliance moves foreign agribusiness and food companies must make before the provisions take effect in 2027.

China's travel rebound is fueling a midscale hotel boom, and international chains are moving in. Four entry moves for foreign hospitality brands targeting value-driven Chinese and inbound travelers.

China's domestic EV market is on track for its first full-year sales decline since 2020 as subsidies phase out and consumer spending softens. What the reversal means for foreign suppliers, and four moves to recalibrate.

Beijing is widening its pharmaceutical anti-kickback crackdown beyond hospital procurement to sales teams, conferences, and distributors. Five compliance moves for foreign drugmakers in China's second-largest pharma market.